EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Metastatic Trajectories in Non–Small Cell Lung Cancer Guide Local and Systemic Therapies

Jonas Willmann iD, Edward Christopher Dee iD, Lizza E L Hendriks iD, Nikolaos M Dimitriou iD, Mandy Jongbloed iD, Adam J Schoenfeld iD, Alexander Drilon iD, Karuna Ganesh iD, Y Helen Zhang iD, Jill Feldman iD, Raphael Werner, Isabelle Opitz iD und 11 weitere

Journal of Clinical Oncology · 01.06.2026 · 44 (16) · 1540-1552

DOI: 10.1200/jco-25-01958 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.06.2026. Verfasst von Jonas Willmann und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 121 Literaturangaben. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Advances in systemic therapy have improved outcomes for metastatic non–small cell lung cancer (NSCLC), yet resistance and progression remain nearly universal. Local therapies such as radiotherapy, surgery, and image-guided ablation can extend disease control in selected patients, but existing classifications—including dynamic models of oligometastatic disease—assign a single state per patient and do not capture lesion-level heterogeneity. We introduce the concept of metastatic trajectories —the spatiotemporal dynamics of response and progression across lesions, organs, and patients—as a framework to characterize intrapatient heterogeneity and inform adaptive treatment strategies. Dimensions of metastatic trajectories include the magnitude and homogeneity of response, mechanisms of resistance, organotropism, and the pattern, site, extent, and pace of progression. This framework shifts the focus from overall disease states to individual lesion behavior over time, enabling reactive strategies based on observed trajectories and anticipatory strategies based on predicted ones. We review the biological foundations of intrapatient heterogeneity—including genomic diversification, nongenetic plasticity, and tumor-microenvironmental adaptation—that drive divergent lesion evolution and treatment response. Emerging biomarkers such as circulating tumor DNA and radiomic signatures, together with integrative genomic and functional imaging approaches, may allow tracking and prediction of trajectory evolution. Standardized reporting parameters are proposed to ensure consistent documentation and facilitate validation across studies. Integrating trajectory-based assessment into clinical practice could refine patient selection for local and systemic therapy, enable biology-informed adaptation of treatment timing and intensity, and provide a foundation for next-generation clinical trials aimed at precision management of metastatic NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansDisease ProgressionNeoplasm MetastasisTumor Microenvironment

Autor:innen und Institutionen

  • Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Pulmonary Diseases, GROW-Research Institute for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands.
  • Halvorsen Center for Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.

ORCID-Profile: Jonas Willmann, Edward Christopher Dee, Lizza E L Hendriks, Nikolaos M Dimitriou, Mandy Jongbloed, Adam J Schoenfeld, Alexander Drilon, Karuna Ganesh, Y Helen Zhang, Jill Feldman, Isabelle Opitz, Jian Carrot-Zhang, Nikolaus Schultz, Harini Veeraraghavan, David R Jones, Mark Awad, Charles M Rudin, Sanjay Popat, Daniel R Gomez, Matthias Guckenberger, Puneeth Iyengar

Förderung

  • NCI NIH HHS

Zitieren

APA

Willmann, J., Dee, E. C., Hendriks, L. E. L., Dimitriou, N. M., Jongbloed, M., Schoenfeld, A. J., Drilon, A., Ganesh, K., Zhang, Y. H., Feldman, J., Werner, R., Opitz, I., Carrot-Zhang, J., Schultz, N., Veeraraghavan, H., Jones, D. R., Awad, M., Rudin, C. M., Popat, S., …, & Iyengar, P. (2026). Metastatic Trajectories in Non–Small Cell Lung Cancer Guide Local and Systemic Therapies. Journal of Clinical Oncology, 44(16), 1540-1552. https://doi.org/10.1200/jco-25-01958

Vancouver

Willmann J, Dee EC, Hendriks LEL, Dimitriou NM, Jongbloed M, Schoenfeld AJ, et al. Metastatic Trajectories in Non–Small Cell Lung Cancer Guide Local and Systemic Therapies. Journal of Clinical Oncology. 2026;44(16):1540-1552. doi:10.1200/jco-25-01958

BibTeX
@article{Willmann2026,
  author = {Willmann, Jonas and Dee, Edward Christopher and Hendriks, Lizza E L and Dimitriou, Nikolaos M and Jongbloed, Mandy and Schoenfeld, Adam J and Drilon, Alexander and Ganesh, Karuna and Zhang, Y Helen and Feldman, Jill and Werner, Raphael and Opitz, Isabelle and Carrot-Zhang, Jian and Schultz, Nikolaus and Veeraraghavan, Harini and Jones, David R and Awad, Mark and Rudin, Charles M and Popat, Sanjay and De Ruysscher, Dirk and Gomez, Daniel R and Guckenberger, Matthias and Iyengar, Puneeth},
  title = {Metastatic Trajectories in Non–Small Cell Lung Cancer Guide Local and Systemic Therapies},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {16},
  pages = {1540--1552},
  doi = {10.1200/jco-25-01958}
}
Kostenlos starten →